Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Daniel Young
New York University School of Medicine, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Syros Pharmaceuticals
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Please see attached report from The Whitehead Institute.
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer
Narrative Small Cell Lung Cancer (SCLC) rapidly develops resistance to first-line chemotherapy. There are currently no treatment options for patients with chemo-refractory disease leading to a very poor prognosis. Building on promising initial results in preclinical SCLC models, this proposal aims to investigate the therapeutic potential of CDK inhibitors for broadly targeting transcriptional and epigenetic dependencies in chemo-refractory SCLC.
Filed on January 02, 2018.
Tell us what you know about Daniel Young's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Daniel Young”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daniel Young | New York University School of Medicine | Conflict of Interest | Marauder Therapeutics | $100,000 - $149,999 |
| Brent Daniel Young | University of Illinois | Financial Disclosure | Daniel 1 Design Build | |
| Daniel Young | New York University School of Medicine | Conflict of Interest | Syros Pharmaceuticals | $100,000 - $149,999 |
| Daniel Young | New York University School of Medicine | Conflict of Interest | Marauder Therapeutics | Value cannot be readily determined |
| Daniel Young | New York University School of Medicine | Conflict of Interest | Omega Therapeutics | $20,000 - $39,999 |
| Daniel Young | New York University School of Medicine | Conflict of Interest | Omega Therapeutics | Value cannot be readily determined |
| Brent Daniel Young | University of Illinois | Financial Disclosure | Daniel One, Inc. |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.